Rankings
▼
Calendar
XLO Q2 2023 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
XLO
Xilio Therapeutics, Inc.
$28M
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$492,000
Operating Income
-$20M
Net Income
-$19M
EPS (Diluted)
$-0.70
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$17M
Free Cash Flow
-$17M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$92M
Total Liabilities
$25M
Stockholders' Equity
$67M
Cash & Equivalents
$75M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$492,000
$0
—
Operating Income
-$20M
-$25M
+18.1%
Net Income
-$19M
-$25M
+21.4%
← FY 2023
All Quarters
Q3 2023 →